Boston Scientific (NYSE:BSX) Price Target Raised to $51.00

Boston Scientific (NYSE:BSX) had its target price lifted by Robert W. Baird from $50.00 to $51.00 in a report issued on Thursday,Benzinga reports. They currently have an outperform rating on the medical equipment provider’s stock.

A number of other equities research analysts have also recently commented on the stock. JPMorgan Chase & Co. cut shares of Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 target price for the company. in a research report on Wednesday. BTIG Research lowered their price target on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 price objective (down from $75.00) on shares of Boston Scientific in a research note on Thursday, July 30th. TD Cowen reiterated a “buy” rating and issued a $56.00 price objective (down from $61.00) on shares of Boston Scientific in a report on Tuesday, October 20th. Finally, Truist Financial decreased their target price on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Stock Down 1.8%

NYSE BSX opened at $41.93 on Thursday. The business has a fifty day moving average price of $44.78 and a 200 day moving average price of $56.88. Boston Scientific has a one year low of $39.57 and a one year high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $60.77 billion, a P/E ratio of 17.77, a P/E/G ratio of 1.03 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the firm posted $0.75 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Research analysts anticipate that Boston Scientific will post 3.17 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 189,522 shares of company stock valued at $9,157,810 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA purchased a new position in Boston Scientific in the second quarter worth $2,156,233,000. Janus Henderson Group PLC grew its position in Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after buying an additional 3,907,981 shares during the period. Amundi grew its holdings in shares of Boston Scientific by 13.8% in the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after acquiring an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after purchasing an additional 2,856,040 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.